Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 1009
An Advocates’ Checklist for Lenacapavir for PrEP Introduction
The Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting HIV PrEP developed a new resource that offers practical guidance to help civil society, advocates and implementers accelerate equitable access to LEN for PrEP. The checklist is designed to support faster, community-centered rollout ahead of broader generic availability in 2027.
Prevention Option:
Lenacapavir Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of May 2026.
Prevention Option:
EXPrESSIVE Phase III Program Countries of MK-8527
Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.
Prevention Option:
PrEP Power Webinar — Global Countries
The recent significant changes to global health funding have severely impacted HIV prevention services for those who need them most, in particular key populations (KPs). Already, some countries are seeing concerning trends in data suggesting a...
Prevention Option:
PrEP Power Webinar — African Countries
The recent significant changes to global health funding have severely impacted HIV prevention services for those who need them most, in particular key populations (KPs). Already, some countries are seeing concerning trends in data suggesting a...
Prevention Option:
Analytical Treatment Interruption (ATI)
In this video, from the Series of Jojo, viewers are introduced to a methodology used to assess the efficacy of cure strategies — Analytical Treatment Interruption (ATI). Watch to learn more.
Prevention Option:
AVAC Infographics for HIV Vaccine Awareness Day
For HIV Vaccine Awareness Day, AVAC’s latest infographics — covering preventive vaccines, bNAbs, the HIV prevention research pipeline, and the impact of US funding cuts — are available as easy-to-use slides.
Prevention Option:
CROI Cure Reflections Video Series
Produced by PAVE (Pediatric Adolescent Virus Elimination), this weekly series of four videos provides HIV cure-related takeaways from CROI 2026.
Prevention Option:
Long-Acting HIV Treatment Pipeline
AVAC has begun to track the research pipeline for long-acting HIV treatment (LA-ART). A rapidly expanding pipeline for LA-ART has the potential to introduce new regimens with dosing frequencies that range from weeks to months to, eventually, years. The benefits of LA-ART include reduced drug dosing, frequency, and number of drugs, with the potential for associated decreases in the cost of medications and the burden on health systems. New drug classes could close treatment gaps in children, adolescents, and those with high viremia, comorbidities and resistance.
Prevention Option:
PxWire Volume 16, Issue 2
This issue showcases AVAC’s analysis of the recent PEPFAR data release, assessing how uptake of prevention programs—particularly PrEP initiations—have declined over the last year. As the field grapples with the lasting impact of the US government’s cuts to PEPFAR programs, AVAC takes a closer look at what the data show and what is still missing.
Prevention Option:
showing 1-10 of 1009